FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. announced a private placement that closed June 29, 2026, raising $3.0 million in gross proceeds under a Securities Purchase Agreement dated June 25, 2026. The company issued pre‑funded warrants (exercise $0.00001) and two series of warrants (exercise $0.735) tied to up to 4,081,633 shares each, plus placement‑agent warrants for 285,714 shares at $0.9188. H.C. Wainwright & Co., LLC served as exclusive placement agent. Net proceeds to the company were approximately $2.6 million after fees and expenses. The warrants (including placement agent warrants) are not exercisable until the company’s stockholders approve issuance of the underlying shares.

Key Details

• Gross proceeds: $3,000,000; net proceeds (after placement agent fees and expenses): ~ $2.6M.
• Securities issued: Pre‑Funded Warrants to purchase up to 4,081,633 shares (exercise $0.00001, no expiration); Short‑term and Long‑term Warrants each to purchase up to 4,081,633 shares (exercise $0.735; short‑term expires 18 months after approval/registration effectiveness, long‑term expires 5 years).
• Placement agent: H.C. Wainwright received a 7% cash fee, 1% management fee, reimbursement of $50,000 legal fees, and Placement Agent Warrants for 285,714 shares at $0.9188 (subject to shareholder approval).
• If all investor warrants are exercised for cash after stockholder approval, FibroBiologics would receive up to ~ $6.0M additional gross proceeds; exercise is subject to shareholder approval and beneficial‑ownership limits (generally 4.99%).

Why It Matters
This financing provides immediate working capital and general corporate funding (~$2.6M net) for FibroBiologics. The issuance of multiple warrant series creates potential future capital (up to ~$6.0M if exercised for cash) but also a source of possible dilution for current shareholders if the warrants are approved by stockholders and exercised. Stockholder approval is required before the warrants (and placement agent warrants) can be exercised for shares; until then, the potential dilution and any related cash inflow remain uncertain. Registration rights were granted to enable resale of the shares underlying the warrants once the company files and the registration statement becomes effective.